Oestrogen treatment of adolescent tall girls; short term side effects

Acta Endocrinol Suppl (Copenh). 1986:279:170-3. doi: 10.1530/acta.0.112s170.

Abstract

In 1980-1985 680 preadolescent tall girls were treated with pharmacological doses of oestrogen to reduce final height. Indications for the therapy were predicted final height greater than +2.5 SD (180.75 cm), idiopathic scoliosis, and psychosocial problems. Until 1976 141 girls were given diethyl stilboestrol 5 mg daily. By advice of Prader this was then replaced by ethinyl oestradiol and a progestin was given on days 5-10 each month. The mean duration of therapy was close to 2 years. The observed short-term unwanted effects were due to the pharmacological actions of the drugs, (11 girls had galactorrhoea at the end of therapy; no pituitary prolactinoma was observed) or events happening by chance.

MeSH terms

  • Adenoma / chemically induced
  • Adolescent
  • Bromocriptine / therapeutic use
  • Child
  • Diethylstilbestrol / adverse effects
  • Diethylstilbestrol / therapeutic use
  • Estrogens / adverse effects*
  • Estrogens / therapeutic use
  • Ethinyl Estradiol / adverse effects
  • Ethinyl Estradiol / therapeutic use
  • Female
  • Galactorrhea / chemically induced
  • Growth Disorders / drug therapy*
  • Humans
  • Pituitary Neoplasms / chemically induced

Substances

  • Estrogens
  • Bromocriptine
  • Ethinyl Estradiol
  • Diethylstilbestrol